Xi-Kui Tian1,
Hong-Di Lv1,
Qing-Hua Zhao2,
Shao-Jun Hao1,
Xiu-Li Geng1,
Xi-Dong Wang1,
Zheng-Chen Zhang1,
Jian-Chang Zhao1
1The 371st Central Hospital of PLA, Xinxiang 453000, Henan;
2The Jinan Military Institute for Drug Control, Jinan 250000, Shandong, PR China.
For correspondence:- Jian-Chang Zhao
Email: jczhao_2015@163.com
Received: 15 February 2015
Accepted: 7 October 2015
Published: 29 November 2015
Citation:
Tian X, Lv H, Zhao Q, Hao S, Geng X, Wang X, et al.
Effects of Yifukang oral liquid on chemotherapy and radiotherapy-induced toxic and side effects of myelosuppression, leucopenia and gastrointestinal tract disturbances. Trop J Pharm Res 2015; 14(11):2023-2030
doi:
10.4314/tjpr.v14i10.11
© 2015 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Abstract
Purpose: To investigate the effects of Yifukang oral liquid (YFKOL) on chemotherapy- and radiotherapy-induced myelosuppression, leucopenia and gastrointestinal tract disturbances.
Methods: The effects of YFKOL on myelosuppression, leucopenia and gastrointestinal tract disturbances were assessed by cyclophosphamide- and Co60-induced leucopenia in mice, copper sulfate-induced emesis in pigeons, ethanol-induced gastric mucosal lesions in rats, gastric emptying and intestinal propulsion in mice.
Results: In cyclophosphamide- and Co60-induced leucopenia assays, the mean white blood cell count (82.6 and 90.1 × 109/L; 7.3 and 8.2 × 109/L, respectively) and thighbone marrow granulocytes (66.1 % and 67.4 %; 60.8 and 66.5 %, respectively) were significantly (p < 0.05) increased after treatment with YFKOL (15 and 30 mL/kg), compared with the respective control (68.2 and 4.7 × 109/L; 58.2 and 53.1 %). In emesis, gastric mucosal lesions, gastric emptying and intestinal propulsion assays, the mean frequency of emesis (30.8 and 22.3 times, respectively) and ulcer index (39.6 and 26.5, respectively) significantly (p < 0.05) decreased, and the mean gastric emptying (25.0 and 24.0 %) and intestinal propulsion (81.9 and 82.8 %) were significantly (p < 0.05) promoted after treatment with YFKOL (10 and 20 mL/kg), compared with the respective control (54.7 times, 62.8, 42.0 and 68.9 %).
Conclusion: YFKOL may suppress chemotherapy- and radiotherapy-induced myelosuppression, leucopenia and gastrointestinal tract disturbances.
Keywords: Yifukang oral liquid, Gastrointestinal tract disturbances, Leucopenia, Myelosuppression, Tumor, Chemotherapy, Radiotherapy